Keros Therapeutics (KROS) Non-Current Assets (2019 - 2025)

Keros Therapeutics has reported Non-Current Assets for 7 years, with the latest figure at $22.6 million in Q4 2025.

• For the quarter ending Q4 2025, Non-Current Assets fell 16.32% year-over-year to $22.6 million; the trailing twelve-month figure through Dec 2025 stood at $95.5 million (down 3.78% YoY), and the FY2025 full-year result was $22.6 million, down 16.32% from the prior year.
• Non-Current Assets for Q4 2025 stood at $22.6 million, down from $23.5 million in the prior quarter.
• The five-year high for Non-Current Assets was $27.2 million in Q3 2024, with the low at $1.7 million in Q1 2021.
• Historically, Non-Current Assets has averaged $16.5 million across 5 years, with a median of $22.1 million in 2023.
• Annual changes were most pronounced in 2023 — Non-Current Assets soared 466.39% — and 2025, when it decreased 16.32%.
• Keros Therapeutics' Non-Current Assets stood at $3.8 million in 2021, then soared by 451.4% to $21.0 million in 2022, then grew by 8.18% to $22.7 million in 2023, then rose by 18.74% to $27.0 million in 2024, then declined by 16.32% to $22.6 million in 2025.
• The last three Non-Current Assets figures came in at $22.6 million (Q4 2025), $23.5 million (Q3 2025), and $24.4 million (Q2 2025), per Business Quant data.